Get the Stockscreener App
0.8123
0.07%
-0.0006
After Hours:
.81
-0.0023
-0.28%
Biofrontera Inc stock is traded at $0.8123, with a volume of 53,389.
It is down -0.07% in the last 24 hours and down -16.58% over the past month.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
See More
Previous Close:
$0.8129
Open:
$0.7923
24h Volume:
53,389
Relative Volume:
0.42
Market Cap:
$9.46M
Revenue:
$39.19M
Net Income/Loss:
$-16.59M
P/E Ratio:
-0.3723
EPS:
-2.182
Net Cash Flow:
$-9.39M
1W Performance:
-2.79%
1M Performance:
-16.58%
6M Performance:
+24.97%
1Y Performance:
-23.37%
1-Day Range:
$0.7923
$0.8251
1-Week Range:
$0.77
$0.8994
52-Week Range:
$0.536
$1.87
Biofrontera Inc Stock (BFRI) Company Profile
Name
Biofrontera Inc
Sector
Phone
781-245-1325
Address
120 PRESIDENTIAL WAY,, WOBURN
Compare BFRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.8123 | 9.47M | 39.19M | -16.59M | -9.39M | -2.182 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Biofrontera Inc Stock (BFRI) Latest News
What analysts say about Biofrontera Inc AI10 stockContrarian Investment Ideas & Free Daily Top Stock Picks for All Investors - earlytimes.in
Biofrontera (NASDAQ:BFRI) Trading Down 1.5% – Time to Sell? - Defense World
Biofrontera Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Biofrontera completes phase 1 study for expanded Ameluz treatment areas By Investing.com - Investing.com Nigeria
Will Biofrontera Inc. (AI10) stock sustain bullish trend into 2025Market Growth Review & Risk Controlled Swing Alerts - Newser
Why Biofrontera Inc. (AI10) stock attracts HNW investors2025 Big Picture & Safe Entry Momentum Tips - Newser
Why Biofrontera Inc. (AI10) stock is favored by hedge fundsWeekly Trade Analysis & Daily Oversold Stock Bounce Ideas - Newser
Will Biofrontera Inc. Equity Warrant stock outperform growth indexes2025 Investor Takeaways & Risk Controlled Stock Pick Alerts - Newser
Biofrontera completes final patient visit in Phase 1 PK study of Ameluz gel - TipRanks
Biofrontera completes phase 1 study for expanded Ameluz treatment areas - Investing.com
Biofrontera (Nasdaq: BFRI) wraps Ameluz Phase 1 PK trial on trunk, plans 2026 FDA sNDA - Stock Titan
Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC - MSN
Can Biofrontera Inc. (AI10) stock survive global slowdownJuly 2025 Update & High Yield Stock Recommendations - Newser
Why Biofrontera Inc. stock remains on buy listsWatch List & Long Hold Capital Preservation Plans - Newser
Biofrontera Inc. (BFRI) 5.8% in After-hours: Filing for New Drug Application Boosts Stock - Stocks Telegraph
Biofrontera submits sNDA to FDA for skin cancer treatment By Investing.com - Investing.com Australia
Biofrontera Inc. (BFRI) 20.51% in After-hours: Notable Price Surge - Stocks Telegraph
Biofrontera submits sNDA to FDA for skin cancer treatment - Investing.com
Biofrontera Inc. announces filing of supplemental new drug application - marketscreener.com
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT - The Manila Times
Biofrontera (BFRI) files sNDA as Ameluz-PDT shows 65.5% clearance in sBCC trial - Stock Titan
Why global investors buy Biofrontera Inc. (AI10) stockJuly 2025 Selloffs & AI Enhanced Trading Alerts - Newser
Biofrontera (BFRI) Stock Analysis Report | Financials & Insights - Benzinga
What analysts say about Biofrontera Inc Equity Warrant stockVWAP Trading Strategies & Small Budget Trading Portfolio - earlytimes.in
PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST NINE MONTHS OF 2025 - TradingView — Track All Markets
BIOFRONTERA REPORTS RESULTS FOR THE FIRST NINE MONTHS OF 2025 - TradingView
Biofrontera, Inc. Navigates Mixed Earnings Call - MSN
Biofrontera reports Q3 EPS (62c) vs (98c) last year - MSN
Is Biofrontera Inc. stock a top momentum playJuly 2025 Macro Moves & Growth Focused Stock Reports - BỘ NỘI VỤ
Its Stock Has Paid Off Big Time For Biofrontera Inc - Setenews
Is Biofrontera Inc a good long term investmentInsider Buying Signals & Lower Drawdowns With Smart Position Sizing - earlytimes.in
How interest rate cuts could boost Biofrontera Inc. Equity Warrant stock - BỘ NỘI VỤ
Is National Plywood Industries Limiteds Business Model Sustainable Long TermMarket Capitalization Trends & Receive Monthly Expert Trading Blueprints - earlytimes.in
How reliable is Biofrontera Inc. (AI10) stock dividend growthEarnings Growth Summary & Weekly Chart Analysis and Guides - newser.com
Why Biofrontera Inc. Equity Warrant is moving todayJuly 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
Why Biofrontera Inc. (AI10) stock could outperform next yearJuly 2025 Gainers & Consistent Income Trade Ideas - newser.com
News impact scoring models applied to Biofrontera Inc.Weekly Trade Summary & Weekly Hot Stock Watchlists - newser.com
Will Biofrontera Inc. (AI10) stock benefit from commodity supercycleGDP Growth & Safe Entry Trade Reports - newser.com
Biofrontera Inc Stock (BFRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):